Q5128 Injection, cimerli, 0.1 milligrams
Also known as: Cimerli injection, pembrolizumab-cmkc
Injection of Cimerli, pembrolizumab-cmkc biosimilar per 0.1 milligrams, a programmed cell death receptor-1 inhibitor.
In Plain Language
immune checkpoint inhibitor; cancer immunotherapy
Clinical Context
Used for various cancers including melanoma, lung cancer, and head and neck cancers.
RVU Information
CPT Q5128 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5128?
CPT Q5128 (Injection, cimerli, 0.1 milligrams) is a Q Codes code. Injection of Cimerli, pembrolizumab-cmkc biosimilar per 0.1 milligrams, a programmed cell death receptor-1 inhibitor.
Is Q5128 covered by insurance?
Q5128 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for various cancers including melanoma, lung cancer, and head and neck cancers.
When is CPT Q5128 used?
Used for various cancers including melanoma, lung cancer, and head and neck cancers.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.